CClinicalTrials.gg
CompletedNCT02501174CONSOGUpdated Mar 18, 2026

Study of Elderly Patients With Cancer and Seen in Consultation of Geriatric Oncology in the Nord Pas-de-Calais (CONSOG).

An observational study in Cancer, sponsored by Centre Oscar Lambret. Completed at 15 sites in France. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Centre Oscar Lambret · Observational

Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
2,914
Ages
65 Years and older
Sex
All
01

Study summary

The aim of this study is to establish a common geriatric oncology medical database. The patients concerned are the patients having benefited from a geriatric oncology consultation in one of the participating centres. This database is designed with a view on the one hand to better describe to better understand this population and on the other hand to facilitate the conduct of future retrospective or prospective studies on this population. The constitution of this observatory of patients seen in consultation should facilitate the development of studies from the analysis of data collected, and occasional surveys by the rapid identification of cases. Data from this database could provide clinicians with valuable informative elements of descriptive epidemiology and concerning the organization of care in the geriatric oncology field.

Read the detailed description

The study is presented during the first consultation of oncogeriatric care or after this consultation (for patients having benefited from the consultation between January 2014 and October 2014) : the patient is informed with an information note and is told that he can express its opposition to the use of its clinical data. In case of no opposition from the patient, the referent geriatrician will complete the patient form with the requested data and will forward it for computerized processing.

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • Geriatric oncology
03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's enrollment of 2,914 is above the median of 204 across 1,683 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Centre Oscar Lambret is the lead sponsor of 127 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients included are patients followed in one of the participating centres and not opposing the use of their medical data.

Inclusion criteria

  • Patient seen in consultation of geriatric oncology in one of the participating centres in Nord Pas-de-Calais.
  • Age ≥ 65 years
  • Patient having been informed and not opposing the computerized processing of its data.

Exclusion criteria

Exclusion Criteria:

  • Patient having opposed the use of its medical data.
05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
2,914 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Measurement of the prevalence of different clinical criteria of interest : demographic characteristics, disease state, patient status according to the geriatric criteria (Comprehensive Geriatric Assessment (CGA)).

    Time frame: Up to 5 years

Secondary outcomes

  1. Measurement of the prevalence of different medical and social criteria of interest.

    Patient's life characteristics (place of living, isolation) and the helps set up (presence of a natural caregiver, sources of professional help).

    Time frame: Up to 5 years

  2. Measurement of the association between one or more factors of interest (clinical, biological and medical and social) related to a proposal to amend or not the initially proposed therapeutic strategy.

    Time frame: Up to 5 years

  3. Percentage of patients included in trials.

    Time frame: Up to 5 years

  4. Temporal evolutions of clinical, medical and social characteristics.

    Time frame: Up to 5 years

07

Study locations

15 sites
  • Centre Hospitalier d'Arras
    Arras, France
  • Centre Hospitalier
    Béthune, 62408, France
  • Centre Hospitalier
    Boulogne-sur-Mer, 62200, France
  • Centre Hospitalier, Douai
    Douai, France
  • Centre Hospitalier
    Dunkirk, 59240, France
  • Hospitalier Le Cateau-Cambresis
    Le Cateau-Cambrésis, France
  • Polyclinique de Riaumont
    Liévin, 62800, France
  • CHRU de Lille
    Lille, 59000, France
  • Hôpital Saint Vincent de Paul
    Lille, 59000, France
  • Centre Oscar Lambret
    Lille, 59020, France
  • Hôpital Saint-Philibert
    Lomme, 59160, France
  • Clinique Saint Jean, Roubaix
    Roubaix, France
  • Centre Hospitalier
    Tourcoing, 59200, France
  • Centre de cancérologie Les Dentellières
    Valenciennes, 59300, France
  • Centre Hospitalier
    Valenciennes, 59300, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02501174
Lead sponsor
Centre Oscar Lambret
Responsible party
Sponsor
First posted
Jul 17, 2015
Start date
Oct 2014
Primary completion
Sep 2019
Completion
Sep 2019
Last update
Mar 18, 2026

Study contacts

Cédric GAXATTE, MD
principal investigator · CHRU de Lille

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion